Abstract
Aim:
To study the distribution, metabolism and excretion of S-propargyl-cysteine (SPRC), a novel hydrogen sulfide (H2S) donor, after oral administration in rats.
Methods:
Adult Sprague-Dawley rats were used. The tissue distribution of [35S] SPRC-derived radioactivity was measured using a liquid scintillation counter. The plasma protein binding of SPRC was examined using 96-well equilibrium dialysis. The excretion of SPRC in urine, bile and feces was analyzed using the LC-MS/MS method. The major metabolites in rat biomatrices were identified using MRM information-dependent, acquisition-enhanced product ion (MRM-IDA-EPI) scans on API 4000QTrap system.
Results:
After oral administration of [35S]-SPRC at a dose of 75 mg/kg, [35S] SPRC-derived radioactivity displayed broad biological distribution in various tissues of rats, including its target organs (heart and brain) with the highest in kidney. On the other hand, the binding of SPRC to human, rat and dog plasma protein was low. Only 2.18%±0.61% and 0.77%±0.61% of the total SPRC administered was excreted unchanged in the bile and urine. However, neither intact SPRC nor its metabolites were detected in rat feces. The major metabolic pathway in vivo (rat bile, urine, and plasma) was N-acetylation.
Conclusion:
The preliminary results suggest that SPRC possesses acceptable pharmacokinetic properties in rats.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Abe K, Kimura H . The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci 1996; 16: 1066–71.
Wang R . The gasotransmitter role of hydrogen sulfide. Antioxid Redox Signal 2003; 5: 493–501.
Dello Russo C, Tringali G, Ragazzoni E, Maggiano N, Menini E, Vairano M, et al. Evidence that hydrogen sulphide can modulate hypothalamo-pituitary-adrenal axis function: in vitro and in vivo studies in the rats. J Neuroendoctinol 2000; 12: 225–33.
Laggner H, Hermann M, Esterbauer H, Muellner MK, Exner M, Gmeiner BM, et al. The novel gaseous vasorelaxant hydrogen sulfide inhibits angiotensin-converting enzyme activity of endothelial cells. J Hypertens 2007; 25: 2100–4.
Chu Q, Ling MT, Feng H, Cheung HW, Tsao SW, Wang X, et al. A novel anticancer effect of garlic derivatives: inhibition of cancer cell invasion through restoration of E-cadherin expression. Carcinogenesis 2006; 27: 2180–9.
Cao Y, Adhikari S, Ang AD, Moore PK, Bhatia M . Mechanism of induction of pancreatic acinar cell apoptosis by hydrogen sulfide. Am J Physiol Cell Physiol 2006; 291: C503–10.
Garcia E, Limon D, Perez-De La Cruz V, Giordano M, Diaz-Muñoz M, Maldonado PD, et al. Lipid peroxidation, mitochondrial dysfunction and neurochemical and behavioural deficits in different neurotoxic models: protective role of S-allylcysteine. Free Radic Res 2008; 42: 892–902.
Rose P, Whiteman M, Moore PK, Zhu YZ . Bioactive S-alk(en)yl cysteine sulfoxide metabolites in the genus Allium: the chemistry of potential therapeutic agents. Nat Prod Rep 2005; 22: 351–68.
Wang Q, Liu HR, Mu Q, Rose P, Zhu YZ . S-propargyl-cysteine protects both adult rat hearts and neonatal cardiomyocytes from ischemia/hypoxia injury: the contribution of the hydrogen sulfide-mediated pathway. J Cardiovasc Pharmacol 2009; 54: 139–46.
Wang Q, Wang XL, Liu HR, Rose P, Zhu YZ . Protective effects of cysteine analogues on acute myocardial ischemia: novel modulators of endogenous H2S production. Antioxid Redox Signal 2010; 12: 1155–65.
Pan LL, Liu XH, Gong QH, Zhu YZ . S-Propargyl-cysteine (SPRC) attenuated lipopolysaccharide-induced inflammatory response in H9c2 cells involved in a hydrogen sulfide-dependent mechanism. Amino Acids 2011; 41: 205–15.
Gong QH, Wang Q, Pan LL, Liu XH, Xin H, Zhu YZ . S-propargyl-cysteine, a novel hydrogen sulfide-modulated agent, attenuates lipopolysaccharide-induced spatial learning and memory impairment: involvement of TNF signaling and NF-kappaB pathway in rats. Brain Behav Immun 2011; 25: 110–9.
Gong QH, Pan LL, Liu XH, Wang Q, Huang H, Zhu YZ . S-propargyl-cysteine (ZYZ-802), a sulphur-containing amino acid, attenuates beta-amyloid-induced cognitive deficits and pro-inflammatory response: involvement of ERK1/2 and NF-kappaB pathway in rats. Amino Acids 2011; 40: 601–10.
Ma K, Liu Y, Zhu Q, Liu CH, Duan JL, Tan BK, et al. H2S donor, S-propargyl-cysteine, increases CSE in SGC-7901 and cancer-induced mice: evidence for a novel anti-cancer effect of endogenous H2S? PLoS One 2011; 6: e20525.
Zheng YT, Liu HR, Ma G, Yang P, Zhang L, Gu Y, et al. Determination of S-propargyl-cysteine in rat plasma by mixed-mode reversed-phase and cation-exchange HPLC-MS/MS method and its application to pharmacokinetic studies. J Pharm Biomed Anal 2011; 54: 1187–91.
Nagae S, Ushijima M, Hatono S, Imai J, Kasuga S, Matsuura H, et al. Pharmacokinetics of the garlic compound S-allylcysteine. Planta Med 1994; 60: 214–7.
Yan CK, Zeng FD . Pharmacokinetics and tissue distribution of S-allylcysteine in rats. Asian J Drug Metab Pharmacokinet 2004; 5: 61–9.
Krause RJ, Glocke SC, Elfarra AA . Sulfoxides as urinary metabolites of S-allyl-L-cysteine in rats: evidence for the involvement of flavin-containing monooxygenases. Drug Metab Dispos 2002; 30: 1137–42.
Acknowledgements
This project was supported by the National Drug Innovative Program (2009ZX09301-011) and Traditional Chinese Medicine Modernization (10DZ1972100).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zheng, Yt., Zhu, Jh., Ma, G. et al. Preclinical assessment of the distribution, metabolism, and excretion of S-propargyl-cysteine, a novel H2S donor, in Sprague-Dawley rats. Acta Pharmacol Sin 33, 839–844 (2012). https://doi.org/10.1038/aps.2012.15
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2012.15
